You Should NOT Lower Lantus or Toujeo When Blood Sugars Are Trending Up
Lowering basal insulin (Lantus or Toujeo) when blood glucose is rising is counterintuitive and clinically inappropriate—you should be increasing the dose, not decreasing it. The only scenarios where dose reduction makes sense despite rising glucose are: (1) hypoglycemia is occurring and you're addressing that first, (2) you're switching between insulin formulations that require dose adjustments, or (3) lipodystrophy/injection site issues are causing erratic absorption 1, 2.
When Dose Reduction IS Appropriate (Despite Rising Glucose)
1. Hypoglycemia Takes Priority
- If hypoglycemia is occurring (even with rising average glucose), reduce the insulin dose by 10-20% 1
- Hypoglycemia risk outweighs short-term hyperglycemia concerns—severe hypoglycemia can cause seizures, death, or permanent neurological damage 2
- This is particularly critical with Toujeo, which has a prolonged duration of action (>24 hours) and may delay recovery from hypoglycemia 2
2. Switching FROM Toujeo TO Lantus
- Toujeo has lower glucose-lowering potency unit-for-unit compared to Lantus 2, 3
- When switching from Toujeo to Lantus, you need approximately 10-20% LESS insulin to avoid hypoglycemia
- Clinical trials showed patients required about 10% more Toujeo than Lantus to achieve the same HbA1c 3
- The FDA label explicitly warns: "On a unit-to-unit basis, TOUJEO has a lower glucose lowering effect than LANTUS" 2
3. Adding Prandial Insulin to Basal Regimen
- When initiating prandial (mealtime) insulin, reduce basal insulin by 4 units or 10% of the basal dose if HbA1c <8% 1
- This prevents "stacking" insulin and reduces hypoglycemia risk
- The guideline specifically states: "If A1C <8% (<64 mmol/mol), consider lowering the basal dose by 4 units per day or 10% of basal dose" 1
4. Lipodystrophy or Injection Site Problems
- Repeated injections into areas of lipodystrophy or localized cutaneous amyloidosis cause hyperglycemia due to poor absorption 2
- When patients switch injection sites from affected to unaffected areas, absorption suddenly improves
- This can cause unexpected hypoglycemia, requiring temporary dose reduction 2
- Monitor closely and adjust accordingly
The Standard Approach: Titrate UP When Glucose Is High
For rising blood glucose without hypoglycemia, the evidence-based approach is dose escalation:
- Increase by 2 units every 3 days until fasting plasma glucose reaches goal without hypoglycemia 1
- Target fasting glucose <100 mg/dL (5.5 mmol/L) 4
- More aggressive titration (increase by 2 IU every 3 days) achieves better HbA1c reduction 4
- Recent real-world data confirms sustained HbA1c improvements with appropriate Toujeo titration (mean reduction -0.85% at 12 months) 5
Critical Pitfall: Toujeo's Delayed Onset
Toujeo has a 6-hour onset of action and doesn't reach full glucose-lowering effect for at least 5 days 2:
- Don't prematurely increase doses—wait 5 days to assess full effect
- When initiating Toujeo, monitor glucose daily and titrate gradually 2
- This delayed pharmacodynamic profile means you need patience during dose adjustments
Special Considerations
Renal or Hepatic Impairment
- These patients have higher hypoglycemia risk 2
- More frequent glucose monitoring required
- May need dose reductions even with suboptimal glucose control
"Overbasalization" Signals
- Large bedtime-to-morning glucose differentials
- High postprandial-to-preprandial glucose differences
- Recurrent hypoglycemia with persistent hyperglycemia
- High glucose variability
These indicate you need to add other agents (GLP-1 RA, prandial insulin) rather than keep increasing basal insulin 1.
Bottom line: The default response to rising blood glucose is to increase basal insulin doses using evidence-based titration algorithms. Only reduce doses when hypoglycemia is present, when switching between insulin formulations with different potencies, when adding prandial insulin, or when injection site issues are identified.